September 2010 in “European Urology Supplements” Serum triglyceride levels are not linked to prostate cancer risk.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
December 2009 in “Saengmyeong gwahag hoeji/Saengmyeong gwahak hoeji” Thymosin β4 and VEGF are important for blood vessel formation in many organs.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
June 2008 in “The Journal of Urology” Men with urinary symptoms are more likely to have erectile dysfunction, and there's a debate about research methods and authorship ethics.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
January 2007 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” Combining D-004 and finasteride is more effective at reducing prostate enlargement than using either alone.
January 2006 in “Actas Urológicas Españolas” Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.